Tampa, FL – According to filings with the U.S. Securities and Exchange Commission, Morphogenesis is raising $11,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Patricia Lawman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Morphogenesis

Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.

To learn more about Morphogenesis, visit http://www.morphogenesis-inc.com/

Contact:
Patricia Lawman, Chief Executive Officer
813-875-6600
https://www.linkedin.com/in/patricia-lawman-a68477111/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved